CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
10 janv. 2022 06h30 HE | Cullinan Oncology, Inc.
Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. ...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h05 HE | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
VIR_logo_large.jpg
Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h02 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40th Annual J.P....